Nxera Pharma Co.,Ltd. Q3 FY2026 earnings call

Chris Cargill, CEO, outlined three core messages: Nxera is profitable in Japan, discovering in the UK, and partnered with the world.

• Profitability and Growth:

  • Core operating profit of JPY 9.8 billion already exceeds full-year guidance (126% of target).
  • Revenue growth driven by strong commercial performance in Japan and increased milestone payments from global partners.
  • Cost reduction initiatives are underway; core R&D down 20% and SG&A down 11%.

• Japan Commercial Updates:

  • PIVLAZ: Sales up 10% to JPY 9.9 billion; on track for full-year targets following release of practical dosing guides.
  • QUVIVIQ: Sales up 43% to JPY 4.5 billion; license agreement signed with Synmosa for 8 APAC countries; launches planned for Taiwan (H2 this year) and South Korea (next year).
  • Lucerastat: In-licensed from Idorsia for Fabry disease; upfront payment of approx. JPY 1.3 billion. Targets rare disease focus with low development risk due to late-stage status.
  • Vamorolone: GUARDIAN trial showed improved safety vs. corticosteroids; filing expected in Japan next year with launch planned for 2028.

• UK R&D and Partnerships:

  • Seven molecules from the UK discovery platform are in clinical trials, including one in Phase III (direclidine for schizophrenia).
  • Partnerships with Neurocrine, Lilly, AbbVie, and Centessa carry over USD 4.6 billion in potential milestones and royalties.
  • AI integration (NxAQ platform) has reduced hit-finding time by 50% and hit-to-lead time by 45%; first AI-designed molecules to be tested in H1 2027.
  • New pipeline programs include an amylin agonist for obesity and a TSHR modulator for Graves' disease.

• Strategic Vision to 2030:

  • Targeting >JPY 50 billion in revenue and >30% operating margin.
  • Growth drivers include expansion of existing products, new in-licenses (lucerastat, AGAMREE), and partner royalties.
  • Two 'loops': Data loop (AI-enhanced discovery) and Cash loop (partners fund late-stage dev; Japan profits fund discovery).

Total revenue for the first nine months of FY2026 increased by 27% year-on-year to JPY 27.7 billion (approx. 2.77 billion yen). The company achieved core operating profit of JPY 9.8 billion, marking a return to profitability from a loss in the prior year. Revenue is split into two main segments:

1. Commercial Business (Japan/APAC): Generated JPY 14.4 billion in product sales (up from JPY 12.2 billion). This segment contributed JPY 7.1 billion to core operating profit. Key products include PIVLAZ with sales of JPY 9.9 billion (+10% YoY) and QUVIVIQ with sales of JPY 4.5 billion (+43% YoY).

2. Platform/Biotech Venture Business (UK/Global Partnerships): Generated JPY 13.3 billion in milestone/partnered revenue (up 63% from JPY 6.5 billion), contributing JPY 2.7 billion to core operating profit. Reported IFRS operating profit was JPY 3.2 billion.

• Full Year Guidance: Management confirms that core operating profit is already at 126% of the full-year guidance target after nine months.
• Revenue Growth: Maintains long-term target of >JPY 50 billion revenue by 2030, implying ~10% annual growth.
• Margin Expansion: Aims for operating margin above 30% by 2030 and ~40% by 2035.
• Product Launches: Lucerastat NDA expected globally as early as 2029 with Japan launch in early 2030s; Vamorolone launch planned for 2028; AGAMREE launch planned for 2028.
• Milestones: Expect additional milestones from existing partners (Neurocrine, Lilly) in FY2027, particularly upon Phase III data readouts.

• Profitability Volatility: Management explicitly stated they cannot guarantee stable profitability in future quarters due to the lumpy nature of milestone revenue from partnerships.
• Partnership Dependency: Reliance on external partners for late-stage development and commercialization outside Japan creates execution risk dependent on partner success.
• Negotiation Uncertainty: Finalizing new licensing agreements is subject to negotiation timelines and outcomes, which may not close within expected fiscal periods.
• Competitive Landscape: Competitors like Bristol-Myers Squibb (Cobenfy) are already launched in relevant indications, though Nxera argues its molecule has superior safety profiles.

Q: Analyst asked if the company can maintain profitability next year given the reliance on milestone timing and potential drag from the platform business. / A: CFO admitted stable profit cannot be guaranteed due to milestone timing volatility but expressed personal belief that profit will continue next year due to multiple upcoming milestones and growing commercial base. CEO emphasized the discovery platform is a value creator, not a drag, and noted ongoing discussions for new partnerships in FY2027 to support continued profitability.

Q: Analyst asked about the strategy for deciding whether to develop assets internally or out-license them, specifically regarding future licensing frequency. / A: CEO explained the strategy is asset-dependent: programs suited for large-scale North American commercialization (e.g., amylin for obesity) are targeted for early clinical development followed by out-licensing to major pharma. Programs suitable for niche/specialty markets in Japan (e.g., TSH, PTH programs) are developed in-house. The goal is roughly one major licensing transaction per year, though timing is variable.

Q: Analyst asked about the competitive landscape for muscarinic drugs, noting slow starts for competitor Cobenfy, and how Nxera’s direclidine will differentiate. / A: CSO and CEO highlighted that their molecule is selectively designed to activate only M1/M4 receptors, avoiding M2/M3 activity which causes GI/cardio side effects seen with Cobenfy (which hits M2/M3). They believe this superior safety profile will drive adoption despite Cobenfy’s current market challenges, supported by efficient trial execution by partner Neurocrine.

Q: Analyst inquired about the progress of pending partnerships, specifically regarding EP4 and GPR52 assets, asking if deals might close before year-end. / A: CEO stated negotiations are closer to completion than initiation for both assets but declined to specify probabilities or valuations due to confidentiality. He confirmed that while no deal is guaranteed, the company is actively working toward transactions this year and expects further partnership activity in FY2027.

Q: Analyst asked about the rationale behind the newly announced stock option plan and long-term incentive structure. / A: CEO explained the plan is strictly pay-for-performance, designed to align management interests with shareholders by requiring share price growth over a minimum 3-year period. It aims to attract US biotech investors who prefer seeing executive skin-in-the-game, thereby driving international demand and funding further science.